• 1
    Kuipers E, Lundell L, Klinkenberg-Knol E, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 101822.
  • 2
    Lundell L, Miettinen P, Myrvold H, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic GERD Study Group. Gastroenterology 1999; 117: 31926.
  • 3
    Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 7849.
  • 4
    Arnold R. Safety of proton pump inhibitors – an overview. Aliment Pharmacol Ther 1994; 8(Suppl. 1): 6570.
  • 5
    Castell D, Richter J, Vakil N, et al. Sustained heartburn resolution is a good predictor of subsequent symptom status in GERD patients with erosive esophagitis. Gastroenterology 2002; 122: T1495.
  • 6
    Baldi F, Ferrarini F, Longanesi A, Ragazzini M, Barbara L. Acid gastroesophageal reflux and symptom occurrence. Analysis of some factors influencing their association. Dig Dis Sci 1989; 34: 1890– 3.
  • 7
    Castell D, Kahrilas P, Richter J, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 57583.
    Direct Link:
  • 8
    Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 47382.